New hope to shield hearts from cancer drug damage
NCT ID NCT07233499
Summary
This study is testing if a blood pressure medication called nebivolol can protect the heart from damage caused by trastuzumab, a life-saving drug for HER2-positive breast cancer. Researchers will give nebivolol to 56 patients alongside their cancer treatment to see if it helps maintain heart function and improves quality of life. The goal is to allow patients to complete their cancer therapy safely without developing heart problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute- Cairo University- Egypt
RECRUITINGCairo, Egypt
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.